One day out & things go wild…lol So I step away fro the day & people get into a tizzy.
First & most importantly " pharma spending around us".
Has 3 easy counter points.
1. The existing in- place trials with Pfizer, Merck & Incyte do involve $$$. That being drug placements & with Bracelet complete 50/50 cost exposure of the trial. That is not zero & certainly not around Onc.
2. There is & has been for some time a $$ upfront & biobucks licensing deal with A.N for 4 years now.
3. The Pfizer deal comes with contractual first right if refusal regarding phase 3 , Pela for MBc.
Agreed, Oncolytics biotech has not been bought out.....YET.
it has been clearly stated & understood, majority of buyouts start with co- development trials & colaborations.
We want a large pharma to buyout Onc for maximum $$$.
The larger pharma deals have been in the $$ billion(s), ranges discussed.
They, Need to justify that spending , based on a potential future return.
The above mentioned trials are in- place to de-risk ( Onc executive words), the future potential.
Every single deal, event,moment of time had a time before where nothing was happening.
then it did.
It is possible that Onc will get pala to marke via a phase 3 licensing deal, similar to th3 China A.N. Deal.
A buyout, May happen soon after or never.
A buyout could happen tomorrow, next week, month or year.
The market comparables are nice to look at.
Onc appears to be further along & in better shape.
just realize more $$$ takes more time.